Properties of Androphilic Protein

嗜雄蛋白的特性

• 批准号: 62480333
• 负责人: SHIMAZAKI Jun
• 金额: $ 4.16万
• 依托单位: Chiba University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (B)
• 财政年份: 1987
• 资助国家: 日本
• 起止时间: 1987 至 1989
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-62480333/
• 关键词: Androgen receptor; Androphilic protein; progestin-binder; R 1881-binding protein; hypertrophic human prostate; Prostatic cancer; アンドロゲンアフィニティゲル; SC115; R3327

1) Partial purification of androgen receptorAndrogen receptor was prepared from cytosol of hypertrophic human prostate using DNA Sepharose and androgen affinity gel. Affinity binding of androgen receptor with bromacetoxydihydrotestosterone was performed. Fragment of the receptor was electrophoresed at site of 45K2) Progestin-binding protein-inhuman prostateProgestin-binding protein covalently bound with labeled R 5020 migrated at site of 42K, which was different from progesterone receptor of human endometrium. Anti-progesterone receptor antibody did not react with progestin- binding protein.3) Histochemical detection of R 1881-binding proteinR 1881-binding protein defected histochemically was mostly progestin-binding protein. R 1881-binding protein was correlated with response to endocrine therapy and prognotis of stage D2 prostatic cancer. R 1881-protein was independent on expression of ras P21.

1)雄激素受体的部分纯化用DNA琼脂糖凝胶和雄激素亲和凝胶从肥大的人前列腺细胞胞浆中制备雄激素受体。雄激素受体与溴乙酰氧基双氢睾酮进行亲和结合。孕激素结合蛋白-人前列腺孕激素结合蛋白与标记的R5020共价结合后，迁移到42 K位点，与人子宫内膜孕激素受体不同。抗孕激素受体抗体与孕激素结合蛋白不发生反应。3）R1881结合蛋白的组织化学检测组织化学检测发现R1881结合蛋白主要为孕激素结合蛋白。R1881结合蛋白与D2期前列腺癌内分泌治疗的反应和预后相关。R1881蛋白的表达不依赖于ras P21的表达。

项目成果

赤倉功一郎,島崎淳ほか: "Characteristics of progestin binder in hypertrophic human prostate." Endocrinol.Japon.35. 899-906 (1988)

Koichiro Akakura、Jun Shimazaki 等人：“肥大性人类前列腺中孕激素结合剂的特征。Endocrinol.Japon.35 (1988)。”

Shigeru Hara, Jun Shimazaki et al.: "Modalities of chemotherapy and endocrine therapy for growth inhibition of androgen-stimulated mouse carcinoma (Shionogi Carcinoma 115)." The Prostate 11, 107-115, 1987.

Shigeru Hara、Jun Shimazaki 等人：“用于抑制雄激素刺激的小鼠癌（Shionogi Carcinoma 115）生长的化疗和内分泌治疗方式。”

市川智彦,島崎淳ほか: "Progression and selection in heterogeneous tumor composed of androgen-responsive Shionogi Carcinoma 114 and its autonomous subline(Chiba Subline2)." Cancer Res.49. 367-371 (1989)

Tomohiko Ichikawa、Jun Shimazaki 等人：“由雄激素反应性 Shionogi 癌 114 及其自主亚系（Chiba Subline2）组成的异质肿瘤的进展和选择（Cancer Res.49）”。

座間秀一,島崎淳 他: Endocrinol.Japon.34. 279-289 (1987)

Shuichi Zama，Jun Shimazaki 等：Endocrinol.Japon.34（1987）。

座間秀一,島崎淳ほか: "Androgen recptor,testosterone uptake and karyotype in androgen-dependent mouse tumor(SC 115)and its androgen-independent subline(CS 2)." Endocrinol.Japon.34. 279-289 (1987)

Shuichi Zama、Jun Shimazaki 等人：“雄激素依赖性小鼠肿瘤 (SC 115) 及其雄激素非依赖性亚系 (CS 2) 中的雄激素受体、睾酮摄取和核型。Endocrinol.Japon.34。” ）